Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Genprex ( (GNPX) ).
Genprex has entered into a new exclusive license agreement with the University of Pittsburgh, consolidating prior agreements to focus on diabetes gene therapy, targeting Type 1 and Type 2 diabetes. This move strengthens Genprex’s intellectual property portfolio and positions it to potentially disrupt the diabetes market, with the formation of a subsidiary, Convergen Biotech, Inc., to advance the diabetes program separately from its oncology focus.
More about Genprex
Genprex, Inc. is a clinical-stage gene therapy company focusing on developing therapies for cancer and diabetes. The company collaborates with world-class institutions to provide novel treatment approaches, including its innovative diabetes gene therapy that uses an AAV vector to deliver specific genes to the pancreas.
YTD Price Performance: -51.11%
Average Trading Volume: 835,995
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.75M
For a thorough assessment of GNPX stock, go to TipRanks’ Stock Analysis page.
